Found 24 matching trials
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL PHASE1 The purpose of this study is to evaluate the safety and efficiency of autol...
Show More Status
Active Not Recruiting
Location
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Learn More & Join Trial
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor(CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL PHASE1 To evaluate the safety and efficacy of CD19/CD22 Bispecific chimeric antige...
Show More Location
Shanghai General Hospital
Learn More & Join Trial
Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies PHASE1 The study will evaluate safety and efficacy of the CD22-targeted chimeric a...
Show More Learn More & Join Trial
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia PHASE2 Background:
Acute lymphoblastic leukemia (ALL) is a type of blood cancer. ...
Show More Location
National Institutes of Health Clinical Center
Learn More & Join Trial
A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma PHASE1 This is a single arm, open-label, uni-center, phase I study . In this study...
Show More Location
Xiangya Hospital Central South University
Learn More & Join Trial
A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) PHASE1 This is a multi-center, phase I/II trial to evaluate the safety and efficac...
Show More Location
Multiple Locations
Learn More & Join Trial
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia PHASE1 This is a single center, single arm, open-label pilot study to determine th...
Show More Location
Abramson Cancer Center of the University of Pennsylvania
Learn More & Join Trial
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 PHASE1 RATIONALE: Placing a tumor antigen chimeric receptor that has been created ...
Show More Location
Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital
Learn More & Join Trial
Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL PHASE1 The goal of this clinical trial is to study the feasibility and efficacy of...
Show More Location
Henan Province of TCM
Learn More & Join Trial
CART22 Alone or in Combination With huCART19 for ALL PHASE1 This is a single center, open-label, phase 1 study to determine the safety ...
Show More Status
Active Not Recruiting
Location
University of Pennsylvania
Learn More & Join Trial